BRINZOLAMIDE MARKET

INTRODUCTION

A carbonic anhydrase inhibitor called brinzolamide is used to reduce intraocular pressure in people with open-angle glaucoma or ocular hypertension. A generic version of brinzolamide has received approval. A group of drugs known as carbonic anhydrase inhibitors includes brinzolamide.

It lowers the pressure inside the eye. Brinzolamide (AZ opt) is an eye drop used to treat glaucoma and reduce eye pressure. Once opened, eye drops in bottles only last for four weeks, therefore if the bottle has been open for more time than this, do not use the drops. This will lessen the chance of developing eye infections.

It's time to give up fried food, baked goods, and anything whose ingredient list contains hydrogenated or partially hydrogenated oils. Red meat, steak, lard, shortening, and oils are examples of saturated diets that might aggravate glaucoma.

BRINZOLAMIDE MARKET SIZE AND FORECAST

The Global BRINZOLAMIDE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

BRINZOLAMIDE MARKET NEW PRODUCT LAUNCH

Teva Pharmaceuticals' release of Brinzolamide Ophthalmic Suspension 1% in the US market was announced by Indocin. The first generic version of AZOPT® from Teva Pharmaceuticals, Brinzolamide Ophthalmic Suspension 1%, has been made available in the United States by Indocin Remedies.

At its Goa factory, Indocin Remedies Ltd. creates and produces the product for TEVA. The ANDA for Brinzolamide Ophthalmic Suspension 1% was approved by the US Food and Drug Administration and is used to treat open-angle glaucoma and excessive pressure inside the eye caused by ocular hypertension.

The action of Brinzolamide Ophthalmic Suspension 1% is to lessen the fluid content of the eye.

The fact that Indocin was the first to introduce a generic version of AZOPT® (Brinzolamide Ophthalmic Suspension 1%, created by Indocin) onto the American market presents a significant potential for Indocin to provide patients with a generic alternative.

Additionally, it gives us great pleasure to have assisted in the process of creating complex generic drugs (ophthalmic suspensions) and obtaining US regulatory approval for them, thereby guaranteeing that people have access to high-quality, reasonably priced medications.

With the manufacturing of Brinzolamide API at the Petal ganga plant, Indocin has a competitive advantage in ensuring the continuation of commercial supplies.

BRINZOLAMIDE MARKET COMPANY PROFILE

• Indoco
• Teva
• Springer
• Nirvana Health
• Sandoz

THIS BRINZOLAMIDE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many BRINZOLAMIDE are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global BRINZOLAMIDE and key vendor selection criteria
3. Where is the BRINZOLAMIDE manufactured? What is the average margin per unit?
4. Market share of Global BRINZOLAMIDE market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global BRINZOLAMIDE in-house
6. key predictions for next 5 years in Global BRINZOLAMIDE market
7. Average B-2-B BRINZOLAMIDE market price in all segments
8. Latest trends in BRINZOLAMIDE market, by every market segment
9. The market size (both volume and value) of the BRINZOLAMIDE market in 2024-2030 and every year in between?
10. Production breakup of BRINZOLAMIDE market, by suppliers and their OEM relationship